Tirzepatide is just as effective in reducing cardiovascular risk driven by central adiposity as that driven by general ...

The GLP-1 medication trend has taken the health and wellness world by storm, largely hailed as a game-changer for weight loss ...

Glucagon-like peptide-1 receptor agonists (GLP-1RAs), originally developed for treating diabetes, work by stimulating insulin secretion and suppressing glucagon release, thereby helping regulate blood ...

A new clinical trial showed promising results in curbing alcohol cravings in individuals with moderate alcohol-use disorder.

Novo Nordisk's GLP-1 receptor agonist semaglutide has been shown to ... 1 may reduce craving for alcohol and nicotine via a similar mechanism to its ability to reduce food cravings and help ...

The phase 2 ELAD study of Novo Nordisk's once-daily injectable GLP-1 agonist liraglutide in people ... liraglutide may work through various mechanisms, such as reducing inflammation in the brain ...

Zealand’s CEO Adam Steensberg said that the company is “exactly where it wants to be” in terms of its partnering and ...

"These results suggest that anti-obesity medication use, with relatively safe, effective, and sustainable weight loss, may be ...

Byline: Hank Popeil In the ever-evolving landscape of healthcare, groundbreaking innovations are not merely celebrated for their scientific ingenuity but for their potential to radically improve human ...

While medications such as methadone, buprenorphine, and naltrexone are FDA-approved for treating opioid use disorder, they ...

Altimmune's existence depends almost entirely on the outcome of the Phase 2 trial for pemvidutide in MASH. Learn why ALT ...